consider ahead result
review sever key consider ahead result
includ financi perform manag outlook impact
near-term updat codebreak trial possibl data
abstract titl releas clinic trial updat implement
recent fda guidanc enabl expect readout tezepelumab omecamtiv-
mecarbil remain on-track collabor develop neutral
antibodi capit alloc bd strategi recent spoke
manag potenti impact view
prudent navig uncertainti posit strength updat
model script make adjust drive new pt detail insid
estim revenu vs consensu adj ep vs
consensu long-term revenu outlook consensu increas
recent publish aimovig
tezepelumab omecamtiv-mecarbil market model although expect sale
impact recent spoke manag view
financi well-posit navig prudent exhibit
clinic trial readout time remain on-track anticip flexibl base
fda guidanc believ major focu next updat sotorasib
expect read summer base enrol
complet primari endpoint six-month orr expect bar
monotherapi approv nsclc base docetaxel
expect updat codebreak trial sotorasib codebreak
monotherapi studi alreadi seen data
potenti registr set nsclc patient complet enrol
codebreak combo studi mek pan-
erbb tki codebreak compar studi vs docetaxel
nsclc
look forward abstract titl wed april potenti confirm
sotorasib data updat expect relat question earn call
follow day expect monotherapi data suspect
might sotorasib plu combo data small patient number
would also encourag bite abstract
bd capit alloc remain top prioriti view
collabor exampl industri leadership view current share price
attract entri point ytd vs nbi
dividend yield provid support updat model script
adjust drive new vs prior exhibit
year price histori
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel stabl
next ten year margin expand manag
track record financi disciplin top line believ
posit maintain long-term revenu stabil
matur product declin new product continu grow
pipelin deliv steadi flow new product
offer dividend yield believ provid valuat
updat data kra inhibitor
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top-lin essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit oppenheim vs consensu estim
exhibit revenu forecast increas steadili
incom estimate oppenheimerv consensu oppenheim estimate consensu updat midpoint total non-gaap cog margin rate incom ep estimate oppenheimerv consensu oppenheim estimate consensu revenu estim pipelinehpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth inc
exhibit long-term revenu outlook gener consensu
exhibit believ financi well-posit withstand prolong pandem cash
balanc estim believ ig-rat
debt provid reason leverag debt/ev interest coverag ratio
compar favor compani debt capit within coverag
total revenu coverag ratiotot debt percent enterpris valu outperform
exhibit sotp analysi valu auto-immun product enbrel otezla
pipelin opportun tezepelumab omecamtiv-mecarbil
exhibit dcf valuat support
drug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successprob-adjust npv mm sotp p-adj valu sharegrowth hpt secondari invest bgne equiti share outstand use valuat analysi except per-shar data revenu incom bgne chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate inc
net incom equiti invest bgne
stock price compani mention report
